ICH Stability Testing & Protocols MCQs With Answer

ICH Stability Testing & Protocols MCQs With Answer

by

Introduction

This quiz collection on ICH Stability Testing & Protocols is designed for M.Pharm students preparing for MIP 102T – Pharmaceutical Formulation Development. It covers core ICH concepts, guideline references, study designs, storage conditions, stress testing, photostability, bracketing and matrixing, batch-size requirements, and interpretation of stability data. Questions are focused on applying regulatory expectations to real formulation development scenarios, emphasizing why stability studies are structured as they are and how results determine shelf life, retest periods and controlled storage. Use these MCQs to assess and deepen your practical understanding of stability protocols and regulatory compliance for drug substances and finished products.

Q1. What ICH guideline specifically addresses stability testing of new drug substances and drug products?

  • ICH Q1A(R2) Stability Testing of New Drug Substances and Products
  • ICH Q1B Photostability Testing
  • ICH Q3A Impurities in New Drug Substances
  • ICH Q5C Stability of Biotechnological Products

Correct Answer: ICH Q1A(R2) Stability Testing of New Drug Substances and Products

Q2. Which of the following storage conditions is the standard ICH accelerated condition for zone II (temperate) used in product registration studies?

  • 25°C ±2°C / 60% RH ±5%
  • 30°C ±2°C / 65% RH ±5%
  • 40°C ±2°C / 75% RH ±5%
  • 5°C ±3°C / ambient RH

Correct Answer: 40°C ±2°C / 75% RH ±5%

Q3. According to ICH Q1B, the recommended minimum light exposure for photostability testing is which of the following?

  • 1.2 million lux hours and 200 watt-hours/square meter near UV
  • 10,000 lux hours and 50 watt-hours/square meter near UV
  • 2 million lux hours and 500 watt-hours/square meter near UV
  • No specific exposure values are defined by ICH Q1B

Correct Answer: 1.2 million lux hours and 200 watt-hours/square meter near UV

Q4. What is the primary purpose of forced degradation (stress testing) during stability protocol development?

  • To accelerate routine long-term stability studies
  • To identify degradation pathways and develop stability-indicating analytical methods
  • To determine packaging compatibility under normal storage
  • To establish photostability exposure limits

Correct Answer: To identify degradation pathways and develop stability-indicating analytical methods

Q5. Which of the following best defines “bracketing” in stability study design?

  • Testing all strengths and container sizes at all time points
  • Testing only the extremes (e.g., highest and lowest strengths) and extrapolating intermediate strengths
  • Testing a subset of batches at each time point in a systematic pattern
  • Testing only under accelerated conditions

Correct Answer: Testing only the extremes (e.g., highest and lowest strengths) and extrapolating intermediate strengths

Q6. How many primary batches does ICH Q1A(R2) generally recommend for submission stability data of a new finished dosage form?

  • One pilot-scale batch is sufficient
  • Two full-scale production batches
  • At least three primary batches representative of production
  • Five small laboratory batches

Correct Answer: At least three primary batches representative of production

Q7. Which of the following is NOT a typical stress condition applied in forced degradation studies?

  • Hydrolytic (acid/base)
  • Oxidative
  • Magnetic field exposure
  • Photolytic and thermal stress

Correct Answer: Magnetic field exposure

Q8. What is the difference between a “retest period” and “shelf life”?

  • Retest period applies to finished products; shelf life applies to APIs
  • Retest period is for APIs (when to retest); shelf life is for finished products (expiry date)
  • They are synonyms and used interchangeably
  • Retest period is for storage at cold conditions only

Correct Answer: Retest period is for APIs (when to retest); shelf life is for finished products (expiry date)

Q9. In stability indicating method development, what key property must the analytical method demonstrate?

  • High throughput regardless of specificity
  • Capability to separate and quantitate drug substance from its degradation products
  • Only quantitation of the parent drug is necessary
  • Exclusive use of UV detection

Correct Answer: Capability to separate and quantitate drug substance from its degradation products

Q10. Which climatic zone corresponds to hot and humid conditions that often require long-term testing at 30°C/75% RH?

  • Zone I
  • Zone II
  • Zone III
  • Zone IV

Correct Answer: Zone IV

Q11. What is matrixing in the context of stability study design?

  • Testing all attributes of a single batch at every time point
  • Testing a planned subset of the total number of samples at each time point to reduce workload
  • Running both accelerated and long-term studies simultaneously
  • Using different analytical methods for different batches

Correct Answer: Testing a planned subset of the total number of samples at each time point to reduce workload

Q12. Which component is essential to include in a stability protocol?

  • List of analytical methods and acceptance criteria
  • Manufacturing route only, without test points
  • Marketing strategy for the product
  • Only storage locations without temperatures

Correct Answer: List of analytical methods and acceptance criteria

Q13. According to ICH, what is typically considered a “significant change” in assay for drug product during accelerated stability testing?

  • Any change regardless of magnitude
  • More than 1% change from initial value
  • More than 5% change from initial value or outside specification
  • Any change in color only

Correct Answer: More than 5% change from initial value or outside specification

Q14. For photostability testing, which of the following is true regarding packaging during exposure?

  • All packaged products must always be tested in final packaging only
  • Both packaged and unpackaged (or in clear container) samples are usually tested to assess product and packaging effects
  • Only bulk drug substance is tested; packaging is irrelevant
  • Opaque packaging always invalidates photostability data

Correct Answer: Both packaged and unpackaged (or in clear container) samples are usually tested to assess product and packaging effects

Q15. Which guideline covers evaluation of stability data and statistical approaches to shelf-life estimation?

  • ICH Q1A(R2)
  • ICH Q1E Evaluation of Stability Data
  • ICH Q2 Analytical Validation
  • ICH Q5C Biotechnological Stability

Correct Answer: ICH Q1E Evaluation of Stability Data

Q16. What is the recommended approach when a stability test result is out-of-specification (OOS)?

  • Immediately withdraw the product without investigation
  • Conduct a thorough investigation including sample integrity, analytical method performance, and production history
  • Ignore single OOS if others are within limits
  • Adjust the specification to include the OOS value

Correct Answer: Conduct a thorough investigation including sample integrity, analytical method performance, and production history

Q17. In accelerated stability studies, why are intermediate conditions sometimes used (e.g., 30°C/65% RH)?

  • To simulate storage at refrigeration temperatures
  • To provide additional data when accelerated results show significant change and long-term data are not yet available
  • To replace long-term studies entirely
  • To test only photostability

Correct Answer: To provide additional data when accelerated results show significant change and long-term data are not yet available

Q18. Which of the following best describes a stability-indicating assay?

  • An assay that is the fastest available method
  • An assay capable of accurately and specifically measuring the active ingredient in presence of degradation products, impurities and excipients
  • An assay that only measures impurities
  • An assay that uses only colorimetric detection

Correct Answer: An assay capable of accurately and specifically measuring the active ingredient in presence of degradation products, impurities and excipients

Q19. When determining container-closure suitability during stability testing, which factor is LEAST relevant?

  • Permeability to moisture and oxygen
  • Interaction between product and container material
  • Color preference of marketing team
  • Protection from light when photolabile

Correct Answer: Color preference of marketing team

Q20. For a new drug substance intended for global registration, why is it important to design stability studies considering ICH climatic zones?

  • Because each zone requires different packaging materials be used
  • Because long-term storage conditions and humidity differ across zones and can affect shelf life and label storage instructions
  • Because zones determine the price of the product
  • Because zones specify which analytical methods are allowed

Correct Answer: Because long-term storage conditions and humidity differ across zones and can affect shelf life and label storage instructions

Leave a Comment